Search results for: Maria Lowe
Filter search results
The Road to Sustainability in the UK and German Biotechnology Industries
1 August 2000
…developed such as incubator laboratories, training and recruitment of local experts in patent law, and provision of business development planning and other services. Public money and lower-risk bank finance have…
Dementia: The R&D Landscape
1 November 2015
…observations include: R&D costs are higher for neurology and Alzheimer’s disease (AD) (as well as respiratory and oncology) than other therapy areas Higher costs are likely due to lower success…
The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries
5 January 2018
…being lower. The value at which prices are currently set in a single-price system will impact on the consequences of a move to a multiple-price system. A number of US…
Establishing a Reasonable Price for an Orphan Drug
1 July 2018
…and development (R&D) cost of an orphan drug is around the 27% of the cost of a non-orphan. However, potential market revenue is also lower for orphan drugs compared to…
Unrelieved Pain in Palliative Care in England
1 September 2019
…their lowest since palliative care is excellent in hospices, there would still be 50,709 palliative care patients dying in some level of pain each year. Of these patients, 5,298 would…
The Inflation Reduction Act: Price negotiation underway for the first 10 drugs
29 November 2023
…does not account for rebates and discounts that are applied in practice and net spend is likely to be much lower for many products on this list, given the significant…
Socio-Economic Value of Adult Immunisation Programmes
18 April 2024
…diseases among lower age groups, places immense pressure on healthcare systems already grappling with treatment backlogs and the growing challenges of antimicrobial resistance and other pandemic threats. Shifting Focus to…
Understanding societal preferences for priority by disease severity in England & Wales
14 November 2024
…for more severe diseases in England and Wales. Members of the general population give priority at a substantially lower severity threshold, and the public assigns greater relative value to health…
What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
19 November 2024
…considered only for products which represent value at or below the lower end of the standard NICE threshold or other applicable thresholds”. It should be noted that the application of…